What question did this study set out to answer?

To evaluate the antitumor efficacy and toxicity of autologous peripheral blood T lymphocytes retargeted with the bispecific monoclonal antibody OC/TR and interleukin-2 in patients with advanced epithelial ovarian cancer.

October 4, 1995JNCI Journal of the National Cancer Institute

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

View Full Paper

Ask AI

Bookmark

Authors

SCSilvana CanevariInstitute of Biomedical Technologies GSGerrit StoterAnton Proksch Institut FAFlavio ArientiFondazione IRCCS Istituto Nazionale dei Tumori

Discussion

Member takes

Implication

Phase II trial demonstrates an intraperitoneal response rate of 27% in advanced ovarian cancer, indicating the therapeutic potential of retargeted T-cell immunotherapy.

Key Points

To evaluate the antitumor efficacy and toxicity of autologous peripheral blood T lymphocytes retargeted with the bispecific monoclonal antibody OC/TR and interleukin-2 in patients with advanced epithelial ovarian cancer.
Enrolled 28 patients with FIGO stage III or IV epithelial ovarian cancer who underwent debulking laparotomy prior to immunotherapy to resect tumor burden and define indicator lesions.
Administered two cycles of five daily intraperitoneal infusions of in vitro-activated autologous T lymphocytes retargeted with OC/TR and recombinant interleukin-2, given with (n=11) or without (n=17) a second daily infusion of OC/TR fragments and interleukin-2.
Achieved an overall intraperitoneal response rate of 27% (95% CI = 10%–44%), with surgical and histological evaluation showing three complete responses lasting 18, 23, and 26 months, three partial responses, seven stable disease, and five progressive disease.
Recorded a median time to disease progression of 11 months (95% CI = 6–18 months) among 15 assessable patients combined with those exhibiting stable disease.
Reported mild to moderate transient toxicities, including fever, nausea, emesis, and fatigue, while anti-mouse antibodies developed in 21 of 25 tested patients.

Cite This Study

Canevari et al. (1995) studied this question.

synapsesocial.com/papers/6a6f5547439bab0cabc2c1df https://doi.org/10.1093/jnci/87.19.1463

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial demonstrates an intraperitoneal response rate of 27% in advanced ovarian cancer, indicating the therapeutic potential of retargeted T-cell immunotherapy.

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

Discussion

Member takes

Implication

Key Points

Cite This Study

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider